Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy

Jun Nakashima, Choichiro Ozu, Toru Nishiyama, Mototsugu Oya, Takashi Ohigashi, Hirotaka Asakura, Masaaki Tachibana, Masaru Murai

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives. To assess the prognostic significance of alkaline phosphatase (ALP) flare in 114 patients with metastatic prostate cancer treated with endocrine therapy.Methods. ALP flare was defined as a transient increase of the serum ALP level to 120% or more of the pretreatment value after the initiation of endocrine therapy, followed by a subsequent decrease.Results. Univariate analysis demonstrated that patients with poorly differentiated adenocarcinoma, an extent of disease of 2 or greater, a serum ALP level above twice the upper limit of normal, a serum prostate-specific antigen level greater than 100 ng/mL, an ALP flare, and a hemoglobin level of 12 g/dL or less had a significantly lower survival rate than their respective counterparts. Multivariate Cox's proportional hazards model analysis demonstrated that tumor histologic features and ALP flare were significant prognostic indicators for survival.Conclusions. The results of the present study suggest that the tumor histologic features and the ALP flare are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with endocrine therapy. Copyright (C) 2000 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)843-847
Number of pages5
JournalUrology
Volume56
Issue number5
DOIs
Publication statusPublished - 2000

Fingerprint

Alkaline Phosphatase
Prostatic Neoplasms
Therapeutics
Serum
Survival
Prostate-Specific Antigen
Proportional Hazards Models
Neoplasms
Hemoglobins
Adenocarcinoma
Survival Rate

ASJC Scopus subject areas

  • Urology

Cite this

Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy. / Nakashima, Jun; Ozu, Choichiro; Nishiyama, Toru; Oya, Mototsugu; Ohigashi, Takashi; Asakura, Hirotaka; Tachibana, Masaaki; Murai, Masaru.

In: Urology, Vol. 56, No. 5, 2000, p. 843-847.

Research output: Contribution to journalArticle

Nakashima, J, Ozu, C, Nishiyama, T, Oya, M, Ohigashi, T, Asakura, H, Tachibana, M & Murai, M 2000, 'Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy', Urology, vol. 56, no. 5, pp. 843-847. https://doi.org/10.1016/S0090-4295(00)00755-X
Nakashima, Jun ; Ozu, Choichiro ; Nishiyama, Toru ; Oya, Mototsugu ; Ohigashi, Takashi ; Asakura, Hirotaka ; Tachibana, Masaaki ; Murai, Masaru. / Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy. In: Urology. 2000 ; Vol. 56, No. 5. pp. 843-847.
@article{c2e556f1c46f4326abd0ba662284743a,
title = "Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy",
abstract = "Objectives. To assess the prognostic significance of alkaline phosphatase (ALP) flare in 114 patients with metastatic prostate cancer treated with endocrine therapy.Methods. ALP flare was defined as a transient increase of the serum ALP level to 120{\%} or more of the pretreatment value after the initiation of endocrine therapy, followed by a subsequent decrease.Results. Univariate analysis demonstrated that patients with poorly differentiated adenocarcinoma, an extent of disease of 2 or greater, a serum ALP level above twice the upper limit of normal, a serum prostate-specific antigen level greater than 100 ng/mL, an ALP flare, and a hemoglobin level of 12 g/dL or less had a significantly lower survival rate than their respective counterparts. Multivariate Cox's proportional hazards model analysis demonstrated that tumor histologic features and ALP flare were significant prognostic indicators for survival.Conclusions. The results of the present study suggest that the tumor histologic features and the ALP flare are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with endocrine therapy. Copyright (C) 2000 Elsevier Science Inc.",
author = "Jun Nakashima and Choichiro Ozu and Toru Nishiyama and Mototsugu Oya and Takashi Ohigashi and Hirotaka Asakura and Masaaki Tachibana and Masaru Murai",
year = "2000",
doi = "10.1016/S0090-4295(00)00755-X",
language = "English",
volume = "56",
pages = "843--847",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic value of alkaline phosphatase flare in patients with metastatic prostate cancer treated with endocrine therapy

AU - Nakashima, Jun

AU - Ozu, Choichiro

AU - Nishiyama, Toru

AU - Oya, Mototsugu

AU - Ohigashi, Takashi

AU - Asakura, Hirotaka

AU - Tachibana, Masaaki

AU - Murai, Masaru

PY - 2000

Y1 - 2000

N2 - Objectives. To assess the prognostic significance of alkaline phosphatase (ALP) flare in 114 patients with metastatic prostate cancer treated with endocrine therapy.Methods. ALP flare was defined as a transient increase of the serum ALP level to 120% or more of the pretreatment value after the initiation of endocrine therapy, followed by a subsequent decrease.Results. Univariate analysis demonstrated that patients with poorly differentiated adenocarcinoma, an extent of disease of 2 or greater, a serum ALP level above twice the upper limit of normal, a serum prostate-specific antigen level greater than 100 ng/mL, an ALP flare, and a hemoglobin level of 12 g/dL or less had a significantly lower survival rate than their respective counterparts. Multivariate Cox's proportional hazards model analysis demonstrated that tumor histologic features and ALP flare were significant prognostic indicators for survival.Conclusions. The results of the present study suggest that the tumor histologic features and the ALP flare are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with endocrine therapy. Copyright (C) 2000 Elsevier Science Inc.

AB - Objectives. To assess the prognostic significance of alkaline phosphatase (ALP) flare in 114 patients with metastatic prostate cancer treated with endocrine therapy.Methods. ALP flare was defined as a transient increase of the serum ALP level to 120% or more of the pretreatment value after the initiation of endocrine therapy, followed by a subsequent decrease.Results. Univariate analysis demonstrated that patients with poorly differentiated adenocarcinoma, an extent of disease of 2 or greater, a serum ALP level above twice the upper limit of normal, a serum prostate-specific antigen level greater than 100 ng/mL, an ALP flare, and a hemoglobin level of 12 g/dL or less had a significantly lower survival rate than their respective counterparts. Multivariate Cox's proportional hazards model analysis demonstrated that tumor histologic features and ALP flare were significant prognostic indicators for survival.Conclusions. The results of the present study suggest that the tumor histologic features and the ALP flare are significant prognostic indicators for survival in patients with metastatic prostate cancer treated with endocrine therapy. Copyright (C) 2000 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033790720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033790720&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)00755-X

DO - 10.1016/S0090-4295(00)00755-X

M3 - Article

C2 - 11068314

AN - SCOPUS:0033790720

VL - 56

SP - 843

EP - 847

JO - Urology

JF - Urology

SN - 0090-4295

IS - 5

ER -